Experimental HCV Drugs
Experimental HCV Drugs
AbbVie's Viekirax + Exviera "3D" Hepatitis C Regimen Approved in Europe
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 21 January 2015 00:00
- Written by AbbVie
The European Commission last week approved AbbVie's interferon-free Viekirax plus Exviera combination regimen -- formerly known as "3D" -- for the treatment of genotype 1 chronic hepatitis C. This approval includes people with compensated liver cirrhosis, liver transplant recipients, HIV/HCV coinfected patients, and people on opioid substitution therapy for drug addiction. The commission also approved Viekirax plus ribavirin for HCV genotype 4.
Sofosbuvir/Ledipasvir + Third Drug Cures Most HCV Patients in 6 Weeks
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 21 January 2015 00:00
- Written by Liz Highleyman
A short and well-tolerated regimen of sofosbuvir, ledipasvir, and a third drug -- either GS-9669 or GS-9451 -- taken for as little as 6 weeks can cure a majority of previously untreated people with genotype 1 chronic hepatitis C, including those with traditional predictors of poor response, according to study results published in the January 12 advance edition of The Lancet.
AbbVie's Viekira "3D" Combo for Hepatitis C Wins FDA Approval
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 19 December 2014 00:00
- Written by FDA
The U.S. Food and Drug Association this week approved AbbVie's Viekira Pak for people with genotype 1 chronic hepatitis C, including patients with compensated cirrhosis. The regimen -- formerly known as "3D" -- consists of the HCV NS3/4A protease inhibitor paritaprevir, a ritonavir booster, and the NS5A inhibitor ombitasvir in a once-daily coformulation, taken with the twice-daily non-nucleoside HCV NS5B polymerase inhibitor dasabuvir.
AASLD 2014: ACH-3102 plus Sofosbuvir Cures All Hepatitis C Patients in Phase 2 Study
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 23 December 2014 00:00
- Written by Liz Highleyman
Achillion's second-generation HCV NS5A inhibitor ACH-3102 combined with sofosbuvir (Sovaldi) was well-tolerated and led to sustained virological response in all treatment-naive genotype 1 hepatitis C patients in a Phase 2 proxy study, according to late-breaking findings presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meetinglast month in Boston. Another early study showed promising results for Achillion's nucleotide polymerase inhibitor ACH-3422.
AASLD 2014: AbbVie 3D Cures Recurrent HCV in Most Liver Transplant Recipients Without Cirrhosis
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 25 November 2014 00:00
- Written by Liz Highleyman
AbbVie's 3D regimen (newly named Viekirax + Exviera) demonstrated a sustained virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation who had not yet developed advanced liver fibrosis or cirrhosis, according to results from the CORAL-I study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston and published in the November 11 advance edition of the New England Journal of Medicine.
More Articles...
- Harvoni Coformulation Approved in Europe for Hepatitis C Genotypes 1 & 4
- AASLD 2014: Daclatasvir + Sofosbuvir Demonstrates Good Cure Rate for HCV Genotype 3 Patients
- AASLD 2014: Sofosbuvir + GS-5816 for 12 Weeks Shows High Cure Rates, 8 Weeks Less Effective
- AASLD 2014: Daclatasvir TRIO Regimen Has Good Cure Rates With or Without Cirrhosis
Web Design and Development by